Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06940674 · ClinicalTrials.gov registry record · Phase 3

Adjunctive Cannabidiol for Recovery From Opioid Study

A Phase 3 study of Opioid Use Disorder (OUD), sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
Phase 3
Development phase
450
Enrollment target
2
Study locations

NCT06940674 is a Phase 3 study of Opioid Use Disorder (OUD) that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 450 participants, above the 253-participant average among 7 other Opioid Use Disorder (OUD) trials with a reported enrollment target (78% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06940674, a Phase 3 study of Opioid Use Disorder (OUD), is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
Phase 3
Development phase
450 participants
Enrollment target
2
Study locations

Study Summary

The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD). The first phase of this project was an open cross-over design study in healthy individuals to confirm the safety and pharmacokinetic (PK) effects of CBD (BSPG CBD; Brains Bioceutical). The second phase was a double-blinded randomized controlled trial to determine whether CBD reduces craving and anxiety in individuals with OUD maintained on opioid agonist therapy. This phase 3 trial will determine whether CBD can serve as a potential adjunct treatment to reduce illicit opioid use in individuals with OUD maintained on opioid agonist therapy.

Conditions Studied

Opioid Use Disorder (OUD)

Interventions

  • DRUG Placebo
  • DRUG Cannabidiol

Study Locations (2)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Oregon

  • CODA Treatment Recovery - Portland

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2025-06-13
Est. Completion 2027-08-15
Phase Phase 3

Sponsor

Icahn School of Medicine at Mount Sinai

708 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06940674

The ClinicalTrials.gov registry entry for NCT06940674 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 253-participant average among 7 other Opioid Use Disorder (OUD) trials with a reported enrollment target (78% higher). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder (OUD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06940674 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Oregon.

Frequently Asked Questions

What is clinical trial NCT06940674 about?

NCT06940674 is a clinical study titled "Adjunctive Cannabidiol for Recovery From Opioid Study". The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD). The first phase of this project was an open cross-over design study in healthy individuals to confirm the safety and pharmacokinetic (PK) effects ...

What is the current status of trial NCT06940674?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2025-06-13. Estimated completion is 2027-08-15.

What conditions does trial NCT06940674 study?

This clinical trial studies the following conditions: Opioid Use Disorder (OUD).

What interventions are being tested in trial NCT06940674?

The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).

Who is sponsoring clinical trial NCT06940674?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06940674 being conducted?

This trial has 2 study locations across New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Opioid Use Disorder (OUD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Opioid Use Disorder (OUD)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.